Organogenesis Holdings Inc. ORGO Proceeds From Issuance Of Convertible Preferred Stock

Proceeds From Issuance Of Convertible Preferred Stock at other companies

KKR & Co.KKR

$0-100%

Lexicon PharmaceuticalsLXRX

$26.55M—

QuantumScape Corporation QS

$44.12M—

Maze Therapeutics, Inc. Common StockMAZE

$17.7M—

Evolution Metals & Technologies Corp. EMAT

$5.55M—

Evommune EVMN

$2M—

Other financials

Income statement

See full

Revenue$37.2M-57.1%

Gross profit$63.0M-22.5%

Operating income-$68.9M-158%

Net income-$53.2M-182%

EPS (diluted)-$0.44-159%

Balance sheet

See full

Cash & equivalents$91.4M-16.9%

Total debt$39.4M+24.8%

Total equity$244.6M+0.7%

Total assets$520.0M+11.3%

Cash flow

See full

Operating cash flow$21.1M+206%

CapEx$3.1M-13.2%

Free cash flow$18.0M+176%

Valuation

See full

Market cap$312.68M-23.7%

Enterprise value$260.72M-21.3%

P/E115×—

P/S0.6×-0.3×

Profitability

See full

Gross margin75.9%+0.8pp

Operating margin0.5%—

Net margin0.5%+0.3pp

FCF margin6.9%—

Returns & leverage

See full

Return on equity1.1%+0.6pp

Debt / equity0.2×0.0×

Current ratio3.5×-0.6×

Where this comes from

Reported directly by Organogenesis Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock.

The official record: Organogenesis Holdings Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organogenesis Holdings Inc.'s proceeds from issuance of convertible preferred stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s proceeds from issuance of convertible preferred stock?: Organogenesis Holdings Inc. (ORGO) reported proceeds from issuance of convertible preferred stock of $30.17M in Q4 2024.